MARY DAMERON: Open Payments
NPI 1467426254 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,635 in 26 payments from 13 companies in 2025. Trend: 2023 $2,700 · 2024 $1,397 · 2025 $1,635
Food & beverage: $1,635
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 2 | $247 |
| Amgen Inc. | 2 | $205 |
| ABBVIE INC. | 8 | $192 |
| Supernus Pharmaceuticals, Inc. | 4 | $159 |
| E.R. Squibb & Sons, L.L.C. | 1 | $135 |
| Dexcom, Inc. | 1 | $115 |
| Daiichi Sankyo Inc. | 1 | $108 |
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
| Phathom Pharmaceuticals, Inc. | 1 | $97 |
| Neurocrine BioSciences, Inc. | 1 | $83 |
Products named: Auvelity, VRAYLAR, Qelbree, COBENFY, DEXCOM G7 GSS (161), INJECTAFER, REPATHA, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
